EVALUATION OF COMMERCIALLY AVAILABLE CONVENTIONAL RELEASE MELOXICAM TABLETS (7.5MG)
Abstract
The main objective of the present study was to investigate which of the commercially available brands of Meloxicam tablets of 7.5mg is more bioavailable in lesser time. Four different brands of meloxicam were purchased from the local market and were evaluated comparatively for hardness, friability, weight variation, and disintegration time and dissolution test. In vitro disintegration was carried out in different media to know the effect of different media on disintegration time. The brands were named as “A, B, C, and D”. The brand A shows most abrupt release but after 45minutes the amount of drug screened in each bowl of dissolution apparatus is nearly same.
Key words: Meloxicam, bioavailability, disintegration, dissolution
References
S. V. Kulkarni, R. K. P, M. Patel, Someshwara Rao B,Ramesh B, Ashok Kumar P. Formulation and evaluation of fast disintegrating meloxicam tablets and its comparison with marketed product, International Journal of Pharmacy and Pharmaceutical Sciences 3(1): 91-93 (2011).
Belousov, Y., 2003. “Generics - Myths and Realities,” Remedium [Remedium], in Russian, No.7-8, pp.4-9.
DH RF, 2005. Guide to Clinical Trials. Drugs. Bioavailability and bioequivalence studies.
EMEA, 2001. Note for guidance on the investigation of bioavailability and bioequivalence, London.
FDA, 2003. Guidance for industry: Bioavailability and bioequivalence studies for orally administered drug products, Department of Health and Human Services, Rock-Ville.
Meshkovskii, A., 2003. “Place of generics in the pharmaceutical supply,” Farmateka[Farmateka], in Russian, No.3, pp.103-104.
NIHS, 2000. Guideline for bioequivalence studies for different strengths of oral solid dosage forms, Japan.
Panyushin, R., 2003. “The original and generic drugs : The unity or the struggle of opposites” Pharm.Gazette [Farmacevticheskiy Vestnik], in Russian, No.16, pp.23-25.
Shoenfeld, P., 1999. “Gastrointestinal safety profile of meloxicam: A meta-analysis and systematic review of randomized controlled trials,”Am J Med., Vol.107 (6A), pp.48-54.
Shostak, N., Shemetov, D., 2001. “Efficacy and tolerability of meloxicam (Movalis) syndrome of pain in his lower back when compared with diclofenac,” Scientific and Practical. Revmatol. [Nauchno-prakticheskiy Revmatolog], in Russian, No.1, pp.63-67.
